Variability of Immune Response to CoronaVac in the Indonesian Population: A Retrospective Cohort Study in Bantaeng, South Sulawesi,Indonesia

Authors

Sitti Musafirah Arif, Department of Dermato-Venereology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245.Follow
Juliani Ibrahim, Department of Public Health, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245.
Antariksa P. Winarno, Department of Clinical-Pathology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245.
Andi Nur Anna, Nursing Study Program, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245
Andi Weri Sompa, Department of Neurology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245
Ami Febriza S. Achmad, Department of Physiology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245. Biomedical Research Center, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong - Bogor, West Java, Indonesia.
Nurdiana Nurdiana, Midwifery Study Program, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245
Zulkifli Zulkifli, Pharmacy Study Program, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245
Irwan Ashari, Department of Public Health, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Indonesia. 90245

Abstract

Background: The COVID-19 vaccine, including CoronaVac, is crucial in reducing severe infections and mortality due to COVID-19. However, variability in antibody responses across different populations remains a subject of investigation. This study aimed to evaluate the impact of age and BMI on Immunoglobulin G (IgG) antibody levels three months post-CoronaVac vaccination in a healthy Indonesian cohort.

Methods: A retrospective cohort study was conducted on 299 healthy individuals aged 18–70 in Bantaeng, South Sulawesi, Indonesia. IgG levels against the SARS-CoV-2 spike protein receptor-binding domain (RBD) were measured using enzyme-linked immunosorbent assay (ELISA). Blood samples were collected about 90 ± 7 days after the second dose of the vaccine. Baseline IgG levels before vaccination were not measured. However, all participants were confirmed to be immunologically naïve based on the absence of COVID-19 symptoms or infection history. The associations between IgG levels, age, and BMI were analyzed using non-parametric statistical tests.

Results: Detectable levels of IgG antibodies were observed three months post-vaccination, with a mean concentration of 4.56 mg/dL. Although the youngest age group (18–35 years) and overweight participants exhibited the highest IgG levels, no significant correlations were observed between IgG levels and age (ρ = –0.042, p = 0.7) or BMI (ρ = 0.043, p = 0.5).

Conclusion: IgG responses to CoronaVac were consistent across age and BMI groups, despite expected variation. These findings support its broad use in Indonesia’s diverse population and national vaccination programs.

Keywords: Humoral response, COVID-19 vaccines, Inactivated vaccines, Indonesia

Recommended Citation

Arif S, Ibrahim J, Winarno AP, et al. Variability of Immune Response to CoronaVac in the Indonesian Population: A Retrospective Cohort Study in Bantaeng, South Sulawesi,Indonesia. J Health Res. 2025; 39(4):-. DOI: https://doi.org/10.56808/2586-940X.1152

References

[1] Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med 2022 Apr;28(4):831e7. https://doi.org/10.1038/s41591-022-01699-1.

[2] Güzel EÇ, Çelikkol A, Erdal B, Sedef N. Immunogenicity after CoronaVac vaccination. Rev Assoc Med Bras 2021 Oct; 67(10):1403e8. https://doi.org/10.1590/1806-9282.20210389.

[3] Rotty I, Kristanto EG, Sekeon S, Ekawardani N, Liwe HR. Formation of SARS-CoV-2 specific antibody after vaccination. eCL 2022 Jan 18;10(1):16.

[4] Nugraheny DE, Prabowo D. Indonesian Foreign Minister Highlights Inequitable Global COVID-19 Vaccine Distribution. Kompas.com. [cited 2025 Jan 10]. Available from: https://nasional.kompas.com/read/2021/09/10/17160291/menlu-sebut-ketimpangan-distribusi-vaksin-covid-19-didunia-masih-terjadi.

[5] Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The capacity of the Indonesian Healthcare System to respond to COVID-19. Front Public Health 2021 Jul 7;9:649819. https://doi.org/10.3389/fpubh.2021.649819.

[6] Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID19. Front Immunol 2020 Oct 14;11:585354. https://doi.org/10. 3389/fimmu.2020.585354.

[7] Santi T, Sungono V, Kamarga L, Samakto BD, Hidayat F, Hidayat FK, et al. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin Exp Vaccine Res 2022 May; 11(2):209e16. https://doi.org/10.7774/cevr.2022.11.2.209.

[8] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021 Jan 9; 397(10269):99e111. https://doi.org/10.1016/S0140-6736(20)32661-1.

[9] Nasr MJC, Geerling E, Pinto AK. Impact of obesity 9 on vaccination to SARS-CoV-2. Front Endocrinol 2022 Jun 20;13: 898810.

[10] Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev 2019 Mar 13; 32(2):e00084. https://doi.org/10.1128/CMR.00084-18.18.

[11] Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020 May;19(5):305e6. https://doi.org/10.1038/d41573-020-00073-5.

[12] Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Sci Technol Humanit 2020 May 29;368(6494):948e50. https://doi.org/10.1126/science.abc5312.

[13] Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med 2021 Aug;27(8):1338e9. https://doi.org/10.1038/s41591-021-01459-7.

[14] Halim M. A report on COVID-19 variants, COVID-19 vaccines and the impact of the variants on the efficacy of the vaccines. J Clin Med Res 2021;3(3):1e19. https://doi.org/10.37191/Mapsci-2582-4333-3(3)-066.

[15] Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One 2021 Jun 16;16(6):e0249499. https://doi.org/10.1371/journal.pone.0249499.

[16] Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother 2021 Mar;53(1):155e8. https://doi.org/10.3947/ic.2021.0302.

[17] Harapan BN, Harapan T, Theodora L, Anantama NA. From archipelago to pandemic battleground: unveiling Indonesia’s COVID-19 crisis. J Epidemiol Glob Health 2023 Dec;13(4): 591e603. https://doi.org/10.1007/s44197-023-00148-7.

[18] Arif SM, Fitriani DA, Carisma SN. The relationship between knowledge and willingness COVID-19 vaccination among adolescence, in Samarinda, Indonesia. Int J Adv Med. 2024 Apr 26;11(3):173e8. https://doi.org/10.18203/2349-3933.ijam20241009.

[19] UNICEF Indoneisa. COVID-19 vaccine acceptance survey in Indonesia. Ministry of Health of the Republic of Indonesia, ITAGI, UNICEF, WHO. 2020 [cited 2025 Jan 10]. Available from: https://www.unicef.org/indonesia/media/7641/file/Survei%20Penerimaan%20Vaksin%20COVID-19.pdf.

[20] Lemeshow S. Adequacy of sample size in health studies. New York: Wiley; 1990.

[21] Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Geneva: WHO; 1991.

[22] Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, et al. Persistence of Anti-SARS-CoV2 Spike IgG antibodies Following COVID-19 Vaccines. I Infect Drug Resist 2022 Jul 29;15:4127e36. https://doi.org/10.2147/IDR.S362848.

[23] Brlic PK, Pavletic M, Lerga M, Krstanovic F, Matesic MP, Miklic K, et al. SARS-CoV-2 spike and nucleocapsid antibody response in vaccinated Croatian healthcare workers and infected hospitalized patients: a single center cohort study. Viruses 2022 Sep 4;14(9):1966. https://doi.org/10.3390/v14091966.

[24] Chansaenroj J, Yorsaeng R, Puenpa J, Wanlapakorn N, Chirathaworn C,Sudhinaraset N,etal.Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS One 2022 Apr 21;17(4): e0267102. https://doi.org/10.1371/journal.pone.0267102.

[25] Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol 2022 Jan; 94(1):173e7. https://doi.org/10.1002/jmv.27289.

[26] Witkowski JM, Fulop T, Bryl E. Immunosenescence and COVID-19. Mech Ageing Dev 2022 Jun;204:111672. https://doi.org/10.1016/j.mad.2022.111672.

[27] Crooke Stephen N, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019 Sep 13;16:25. https://doi.org/10.1186/s12979-019-0164-9.

[28] Damiot A, Pinto AJ, Turner JE, Gualano B. Immunological implications of physical inactivity among older adults during the COVID-19 pandemic. Gerontology 2020;66(5):431e8. https://doi.org/10.1159/000509216.

[29] Schaffer AL, Hulme WJ, Horne E, Parker EPK, Walker V, Stables C, et al. Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: regression discontinuity analysis in OpenSAFELY-TPP. Vaccine 2025 May 20;59:127257. https://doi.org/10.1016/j.vaccine.2025.127257.

[30] Tretyn A, Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Sandomierz D, Dejewska J, et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells 2021 Jul 31;10(8):1952. https://doi.org/10.3390/cells10081952.

[31] Golec M, Zembala-John J, Fronczek M, Konka A, Bochenek A, Wystyrk K, et al. Relationship between anthropometric and body composition parameters and antiSARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: Acohort study. PLoS One 2023 Jun 13;18(6):e0287128. https://doi.org/10.1371/journal.pone.0287128.

[32] Malavazos AE, Basilico S, Iacobellis G, Milani V, Cardani R, Boniardi F, et al. Antibody responses to BNT162b2 mRNA vaccine: Infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring) 2022 Mar;30(3): 606e13. https://doi.org/10.1002/oby.23353.

[33] Dicker D, Golan R, Baker JL, Busetto L, Frühbeck G, Goossens GH, et al. Vaccinating people with obesity for COVID-19: EASO call for action. O Obes Facts 2021;14(3): 334e5. https://doi.org/10.1159/000516524.

[34] Fu C, Lin N, Zhu J, Ye Q. Association between overweight/ obesity and the safety and efficacy of COVID-19 vaccination: a systematic review. Vaccines (Basel) 2023 May 17;11(5):996. https://doi.org/10.3390/vaccines11050996.

[35] Ou X, Jiang J, Lin B, Liu Q, Lin W, Chen G, et al. Antibody responses to COVID-19 vaccination in people with obesity: A systematic review and meta-analysis. Influenza Other Respir Viruses 2023 Jan;17(1):e13078. https://doi.org/10.1111/irv.13078.

[36] Faizo AA, Qashqari FS, El-Kafrawy SA, Barasheed O, Almashjary MN, Alfelali M, et al. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity. J Med Virol 2023 Jan;95(1):e28130. https://doi.org/10.1002/jmv.28130.

[37] Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel) 2021 Feb 16;9(2):160. https://doi.org/10.3390/vaccines9020160.

[38] Jin L, Li Z, Zhang X, Li J, Zhu F. CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum Vaccines Immunother 2022 Nov 30;18(6):2096970. https://doi.org/10.1080/21645515.2022.2096970.

[39] Hu L, Sun J, Wang Y, Tan D, Cao Z, Gao L, et al. A review of inactivated COVID-19 vaccine development in china: focusing on safety and efficacy in special populations. Vaccines (Basel) 2023 May 31;11(6):1045. https://doi.org/10.3390/ vaccines11061045.

[40] WHO Strategic Advisory Group of Experts on Immunization, the SAGE Working Group on COVID-19 vaccines. Evidence assessment: SinoVac/CoronaVac COVID-19 vaccine. 2022 [cited 20258 Jan 10]. Available from: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf.

[41] Utami A, Margawati A, Pramono D, Nugraheni A, Pramudo S. Determinant factors of COVID-19 vaccine hesitancy among adult and elderly population in Central Java, Indonesia. Patient Prefer Adherence 2022 Jun 28;16:1559e70. https://doi.org/10.2147/PPA.S365663.

[42] Hafiz I, Illian DN, Meila O, Utomo ARH, Susilowati A, Susetya IE, et al. Effectiveness and efficacy of vaccine on mutated SARS-CoV-2 virus and post vaccination surveillance: a narrative review. Vaccines (Basel) 2022 Jan 6;10(1):82. https://doi.org/10.3390/vaccines10010082.

[43] Palacios R, Batista AP, Albuquerque CSN, Pati~ no EG, SantosJDP,TilliReisPessoaCondeM,etal.Efficacyandsafety of a COVID-19inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study [cited 2025 Feb 20]; Available from:. 2021. https://www.ssrn.com/abstract=3822780.